Flow cytometry analysis of acute promyelocytic leukemia: the power of ‘surface hematology’

[1]  F. Mandelli,et al.  Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features , 2007, Leukemia.

[2]  L. Platanias,et al.  Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. , 2006, Cancer research.

[3]  S. Alkan,et al.  A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all‐trans retinoic acid) therapy , 2006, European journal of haematology.

[4]  K. Hunter,et al.  Mapping normal and cancer cell signalling networks: towards single-cell proteomics , 2006 .

[5]  F. Lo Coco,et al.  Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. , 2006, Clinical advances in hematology & oncology : H&O.

[6]  Karel Drbal,et al.  CD molecules 2005: human cell differentiation molecules. , 2005, Blood.

[7]  P. Chattopadhyay,et al.  Seventeen-colour flow cytometry: unravelling the immune system , 2004, Nature Reviews Immunology.

[8]  M. Ruthardt,et al.  Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell , 2004, Leukemia.

[9]  D. Neuberg,et al.  A surrogate marker profile for PML/RARα expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes , 2004, Cytometry. Part B, Clinical cytometry.

[10]  T. Enver,et al.  Acute promyelocytic leukemia: where does it stem from? , 2004, Leukemia.

[11]  D. Swirsky,et al.  Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence. , 2004, Cancer genetics and cytogenetics.

[12]  M. Ruthardt,et al.  Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell. , 2004, Leukemia.

[13]  E. Paietta,et al.  Expression of cell-surface antigens in acute promyelocytic leukaemia. , 2003, Best practice & research. Clinical haematology.

[14]  C. Peschle,et al.  C-fms expression correlates with monocytic differentiation in PML-RARα+ acute promyelocytic leukemia , 2003, Leukemia.

[15]  C. Craddock,et al.  The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells. , 2002, Cancer research.

[16]  B. Falini,et al.  Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. , 2002, Blood.

[17]  F. Lo Coco,et al.  CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Dello Russo,et al.  In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family. , 1999, Tissue antigens.

[19]  P. Nowell,et al.  Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia. , 1999, American journal of clinical pathology.

[20]  J. Hernández-Rivas,et al.  The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. , 1999, Haematologica.

[21]  J. Byrd,et al.  CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Leber,et al.  PML/RARα APL with undifferentiated morphology and stem cell immunophenotype , 1998, Leukemia.

[23]  V. Gangadharan,et al.  Acute promyelocytic leukaemia : the era of ATRA. , 1998 .

[24]  B. Leber,et al.  PML/RAR alpha APL with undifferentiated morphology and stem cell immunophenotype. , 1998, Leukemia.

[25]  E. Schiavone,et al.  Stem cell factor receptor (c‐kit, CD117) is expressed on blast cells from most immature types of acute myeloid malignancies but is also a characteristic of a subset of acute promyelocytic leukaemia , 1996 .

[26]  W. Erber,et al.  Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies , 1994, British journal of haematology.

[27]  J. Bennett,et al.  The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. , 1994, Leukemia.

[28]  E. Schiavone,et al.  Expression and ATRA-driven modulation of adhesion molecules in acute promyelocytic leukemia. , 1994, Leukemia.

[29]  H. Miyachi,et al.  MDR1 (multidrug resistance) gene expression in adult acute leukemia: correlations with blast phenotype. , 1993, International journal of hematology.

[30]  F. Mandelli,et al.  Immunological definition of acute promyelocyte leukemia (FAB M3): A study of 39 cases , 1990, European journal of haematology.

[31]  T. Uchida,et al.  Expression of monocytic and T-lymphocytic phenotype in a variant form of acute promyelocytc leukaemia (M3) , 2009 .

[32]  H. Zola,et al.  Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification , 1986, British journal of haematology.